Loading
Led KEYNOTE-048, which made pembrolizumab first-line therapy for recurrent or metastatic head and neck cancer.
Barbara Burtness (Yale Cancer Center) was principal investigator of KEYNOTE-048, which showed pembrolizumab alone or with chemotherapy improves survival over the EXTREME regimen in recurrent or metastatic head and neck squamous cell carcinoma, establishing PD-1 blockade first line. She chaired the ECOG-ACRIN head and neck committee for many years and led the early cetuximab trials in the disease.
Shares PD-1, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tags head-and-neck, immunotherapy.
Shares PD-1, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag head-and-neck.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-1, Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Head and neck squamous cell carcinoma and the tags head-and-neck, immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Yale Cancer Center / Smilow Cancer Hospital, EGFR, PD-1, Pembrolizumab and the tag immunotherapy.
Shares PD-1, Pembrolizumab, Immune checkpoint inhibitors and the tag immunotherapy.